Regeneron Pharmaceuticals Inc (REGN)
Company overview
A biotech holding blockbuster antibody drugs such as the macular-degeneration drug Eylea and the atopic-dermatitis drug Dupixent.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Regeneron Pharmaceuticals Inc is classified under the Biotech & Health sector. See peers below.
ETFs holding Regeneron Pharmaceuticals Inc
Per SEC N-PORT · 2026-03-31 · by weight · factual
REGN on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — valuation and growth vs the Biotech & Health average
Peers · Biotech & Health
REGN FAQ
What is Regeneron Pharmaceuticals Inc (REGN)?
A biotech holding blockbuster antibody drugs such as the macular-degeneration drug Eylea and the atopic-dermatitis drug Dupixent.
What sector is Regeneron Pharmaceuticals Inc in?
Regeneron Pharmaceuticals Inc is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
Where can I analyze Regeneron Pharmaceuticals Inc (REGN) stock?
On Stocklore you can see REGN's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, 45-day delay), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.